Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

1,105 questions in 84 reviews · Metabolic and Endocrine Disorders

current versions

No studies 434 · 39.3%Ungraded 32 · 2.9%Very low 246 · 22.3%Low 237 · 21.4%Moderate 132 · 11.9%High 24 · 2.2%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Intervention NR Change in HbA1c from baseline to endpoint [%] ‐ Sitagliptin versus placebo % ( · type 2 diabetes mellitus Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus (2008) · Cochrane	no estimate extracted	3 studies · 1103 participants	High
Intervention NR Change in body weight from baseline to endpoint ‐ Sitagliptin versus placebo kg ( · type 2 diabetes mellitus Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus (2008) · Cochrane	no estimate extracted	3 studies · 1109 participants	High
Intervention NR Adverse events ‐ All‐cause infections ( · type 2 diabetes mellitus Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus (2008) · Cochrane	RR 1.29 [1.09, 1.52]	8 studies · 3589 participants	High
Intervention NR Morbidity · patients with type 2 diabetes mellitus Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus (2008) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Health‐related quality of life · patients with type 2 diabetes mellitus Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus (2008) · Cochrane	no estimate extracted	NR	No studies